[go: up one dir, main page]

MX2022008124A - Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano. - Google Patents

Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano.

Info

Publication number
MX2022008124A
MX2022008124A MX2022008124A MX2022008124A MX2022008124A MX 2022008124 A MX2022008124 A MX 2022008124A MX 2022008124 A MX2022008124 A MX 2022008124A MX 2022008124 A MX2022008124 A MX 2022008124A MX 2022008124 A MX2022008124 A MX 2022008124A
Authority
MX
Mexico
Prior art keywords
sub
antibody
heavy chain
amino acid
human
Prior art date
Application number
MX2022008124A
Other languages
English (en)
Inventor
Alexander Berthold Hendrik Bakker
Loo Pieter Fokko Van
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2022008124A publication Critical patent/MX2022008124A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La descripción se relaciona con anticuerpos que se unen a CD3 humano que comprenden una cadena pesada y una cadena ligera en donde la cadena pesada comprende una región variable que comprende la secuencia de aminoácidos: QVQLV QSGGG VVQPG RSLRL SCVAS GFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSS con 0 a 5 inserciones, supresiones, sustituciones, adiciones de aminoácidos, o una combinación de los mismos. La descripción también se relaciona con anticuerpos biespecíficos que tienen una cadena pesada como se define en lo anterior. Se proporcionan métodos de producción del anticuerpo, células que producen el anticuerpo y con usos (médicos) del anticuerpo.
MX2022008124A 2015-07-10 2018-01-09 Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano. MX2022008124A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15176355 2015-07-10

Publications (1)

Publication Number Publication Date
MX2022008124A true MX2022008124A (es) 2022-08-08

Family

ID=53673007

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000344A MX2018000344A (es) 2015-07-10 2016-07-08 Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano.
MX2022008124A MX2022008124A (es) 2015-07-10 2018-01-09 Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018000344A MX2018000344A (es) 2015-07-10 2016-07-08 Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano.

Country Status (23)

Country Link
US (4) US9914777B2 (es)
EP (3) EP3345928B1 (es)
JP (3) JP7010811B2 (es)
KR (1) KR102709815B1 (es)
CN (1) CN108026174B (es)
AU (1) AU2016293942B2 (es)
CA (1) CA2991880C (es)
CY (1) CY1120849T1 (es)
DK (1) DK3115376T3 (es)
EA (1) EA201890028A1 (es)
ES (2) ES2812303T3 (es)
HR (1) HRP20181802T1 (es)
HU (1) HUE042039T2 (es)
IL (2) IL321912A (es)
LT (1) LT3115376T (es)
MX (2) MX2018000344A (es)
PL (1) PL3115376T3 (es)
PT (1) PT3115376T (es)
RS (1) RS57928B1 (es)
SI (1) SI3115376T1 (es)
SM (1) SMT201800562T1 (es)
TR (1) TR201816055T4 (es)
WO (1) WO2017010874A1 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20191409T1 (hr) 2012-04-20 2019-11-15 Merus Nv Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
PT2900694T (pt) 2012-09-27 2018-11-13 Merus Nv Anticorpos de igg biespecíficos como ativadores de células t
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
IL274151B (en) 2015-05-21 2022-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
LT3115376T (lt) 2015-07-10 2018-11-12 Merus N.V. Antikūnai, kurie jungiasi su žmogaus cd3
WO2017069628A2 (en) 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
CN119060177A (zh) 2016-05-20 2024-12-03 哈普恩治疗公司 单结构域血清白蛋白结合蛋白质
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
US20180164221A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018182422A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN111148764B (zh) 2017-05-17 2025-08-12 美勒斯公司 用于乳腺癌的ErbB-2/ErbB-3双特异性抗体与内分泌治疗的组合
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
EP3642229A1 (en) 2017-06-21 2020-04-29 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
CN113896797B (zh) 2017-08-01 2023-05-09 Ab工作室有限公司 双特异性抗体及其用途
AU2018312816B2 (en) 2017-08-09 2021-05-27 Merus N.V. Antibodies that bind EGFR and cMET
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EP3694529B1 (en) 2017-10-13 2024-06-26 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
CN111629749A (zh) 2017-10-18 2020-09-04 诺华股份有限公司 用于选择性蛋白质降解的组合物和方法
MX2020004948A (es) 2017-11-15 2020-11-11 Novartis Ag Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación.
WO2019108900A1 (en) 2017-11-30 2019-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
JP2021504413A (ja) * 2017-12-01 2021-02-15 メルス ナムローゼ フェンノートシャップ 組み合わせ治療のための二重特異性抗体及びｉｌ−１５の使用
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
AU2019215031B2 (en) 2018-01-31 2025-10-09 Novartis Ag Combination therapy using a chimeric antigen receptor
TWI804572B (zh) * 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
MX2020010267A (es) * 2018-03-30 2020-11-06 Merus Nv Anticuerpo multivalente.
WO2019224715A1 (en) * 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for cd3 and uses thereof
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
SI3844267T1 (sl) 2018-08-31 2025-10-30 Novartis Ag Postopki izdelave celic, ki izražajo receptorje himernega antigena
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
WO2020069028A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
CN111116753A (zh) * 2018-10-30 2020-05-08 上海泰因生物技术有限公司 一种双特异性抗体的制备方法
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020130829A1 (en) 2018-12-20 2020-06-25 Merus N.V. Clec12axcd3 bispecific antibodies and methods for the treatment of disease
US12463463B2 (en) 2019-01-28 2025-11-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
KR20210134339A (ko) 2019-02-25 2021-11-09 노파르티스 아게 바이러스 전달을 위한 메조다공성 실리카 입자 조성물
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
TW202039578A (zh) * 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
CN114605546A (zh) * 2019-03-29 2022-06-10 美勒斯公司 Cd3结合分子
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
TWI889320B (zh) * 2019-07-05 2025-07-01 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
CA3147103A1 (en) 2019-07-19 2021-01-28 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
US20220281977A1 (en) * 2019-07-30 2022-09-08 Ono Pharmaceutical Co., Ltd. Bispecific antibody
BR112022003143A2 (pt) 2019-08-19 2022-05-17 Merus Nv Tratamento de câncer com uma combinação de um anticorpo que se liga ao lgr5 e ao egfr e um inibidor de topoisomerase i.
KR20220069961A (ko) * 2019-09-13 2022-05-27 메모리얼 슬로안 케터링 캔서 센터 항-cd371 항체 및 그의 용도
MX2022006391A (es) 2019-11-26 2022-06-24 Novartis Ag Receptores de antigeno quimerico que se unen a bcma y cd19 y usos de los mismos.
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CA3166629A1 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
PH12022552283A1 (en) 2020-02-27 2024-01-22 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
BR112022016633A2 (pt) 2020-02-27 2022-12-13 Novartis Ag Métodos para produzir células que expressam receptor de antígeno quimérico
TWI799824B (zh) 2020-03-31 2023-04-21 日商中外製藥股份有限公司 Ｄｌｌ３靶向之多特異性抗原結合分子及其用途
KR20230005281A (ko) 2020-04-24 2023-01-09 메뤼스 엔.페. Lgr5 및 egfr에 결합하는 항체를 사용하는 암의 치료
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
IL300489A (en) 2020-08-21 2023-04-01 Novartis Ag Compositions and methods for in vivo production of CAR expressing cells
KR20230120125A (ko) 2020-12-15 2023-08-16 메뤼스 엔.페. Lgr5 및 egfr에 결합하는 항체를 사용하는 암의 치료
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
US20240384293A1 (en) 2021-04-27 2024-11-21 Novartis Ag Viral vector production system
JP2024525916A (ja) * 2021-07-20 2024-07-12 エイビーエル バイオ インク． 抗ｃｌｌ－１抗体及びその用途
CN117858901A (zh) 2021-08-20 2024-04-09 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
TW202321309A (zh) 2021-10-06 2023-06-01 荷蘭商美勒斯公司 使用至少結合ｅｇｆｒ之抗體治療免疫檢查點抑制劑治療之具高ｅｇｆｒ表現的癌症
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
EP4608983A1 (en) 2022-10-26 2025-09-03 Novartis AG Lentiviral formulations
TW202434635A (zh) * 2022-11-03 2024-09-01 美商翰森生物有限責任公司 多特異性抗體及其醫藥用途
TW202432605A (zh) 2022-12-23 2024-08-16 荷蘭商美勒斯公司 使用至少結合ｅｇｆｒ的抗體和免疫檢查點抑制劑組合治療癌症
AU2023418141A1 (en) 2022-12-28 2025-07-17 Merus N.V. Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs
WO2025097015A1 (en) * 2023-11-01 2025-05-08 Fred Hutchinson Cancer Center Clec2a-binding therapeutics
WO2025109119A1 (en) 2023-11-22 2025-05-30 Priothera Sas Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
ES2199216T3 (es) 1991-07-15 2004-02-16 The Wellcome Foundation Limited Produccion de anticuerpos.
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
EP1533380B1 (en) 1999-04-15 2009-11-04 Crucell Holland B.V. Recombinant protein production in a human cell comprising at least one E1 protein of adenovirus
DK1404872T3 (da) 2001-07-04 2007-02-19 Chromagenics Bv Fremgangsmåde til selektion af en DNA-sekvens med transkriptionsmodulerende aktivitet med en vektor indeholdende et element med en gentranskriptionsundertrykkende aktivitet
US20050130224A1 (en) 2002-05-31 2005-06-16 Celestar Lexico- Sciences, Inc. Interaction predicting device
DK1523496T3 (da) 2002-07-18 2011-10-17 Merus B V Rekombinant fremstilling af blanding af antistoffer
BRPI0406678A (pt) 2003-01-07 2005-12-20 Symphogen As Método para produzir proteìnas policlonais recombinantes
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1636265A2 (en) 2003-06-25 2006-03-22 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
UA94211C2 (ru) 2004-06-03 2011-04-26 Новиммюн С.А. Выделенное полностью человеческое моноклональное cd3 антитело
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
US20060171929A1 (en) 2005-01-31 2006-08-03 The University Of Washington Regulation of dendritic cell functions by the DCAL-2 receptor
EP1871808A2 (en) 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
AU2006291005A1 (en) 2005-09-12 2007-03-22 Novimmune S.A. Anti-CD3 antibody formulations
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
CN101802015B (zh) 2007-03-29 2015-05-06 根马布股份公司 双特异性抗体及其制造方法
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2245571B1 (en) 2008-02-05 2019-04-10 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
WO2009157771A2 (en) 2008-06-27 2009-12-30 Merus B.V. Antibody producing non-human mammals
US20120020952A1 (en) 2009-01-26 2012-01-26 Genmab A/S Methods for producing mixtures of antibodies
EP2408817B1 (en) 2009-03-20 2016-03-16 F.Hoffmann-La Roche Ag Bispecific anti-her antibodies
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MY164121A (en) 2009-06-26 2017-11-30 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP5955781B2 (ja) 2010-02-08 2016-07-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 共通の軽鎖のマウス
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
WO2012020096A1 (en) 2010-08-13 2012-02-16 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
JP5997154B2 (ja) 2010-08-16 2016-09-28 ノビミューン エスアー 多重特異性多価抗体の生成方法
US9562109B2 (en) 2010-11-05 2017-02-07 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP2688909A2 (en) 2011-03-25 2014-01-29 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
HRP20191409T1 (hr) 2012-04-20 2019-11-15 Merus Nv Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
PT2900694T (pt) * 2012-09-27 2018-11-13 Merus Nv Anticorpos de igg biespecíficos como ativadores de células t
JP6003513B2 (ja) * 2012-10-15 2016-10-05 株式会社Ihi 高温処理炉及び強化繊維の継ぎ方法
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
KR102849905B1 (ko) 2014-02-28 2025-08-26 메뤼스 엔.페. ErbB-2와 ErbB-3에 결합하는 항체
LT3115376T (lt) 2015-07-10 2018-11-12 Merus N.V. Antikūnai, kurie jungiasi su žmogaus cd3

Also Published As

Publication number Publication date
US11739148B2 (en) 2023-08-29
AU2016293942A1 (en) 2018-02-01
IL256760A (en) 2018-03-29
HK1254029A1 (zh) 2019-07-12
US10266593B2 (en) 2019-04-23
US20180237523A1 (en) 2018-08-23
CA2991880A1 (en) 2017-01-19
JP7010811B2 (ja) 2022-02-10
CA2991880C (en) 2025-02-04
CY1120849T1 (el) 2019-12-11
RS57928B1 (sr) 2019-01-31
JP2022023228A (ja) 2022-02-07
PL3115376T3 (pl) 2019-01-31
JP7772759B2 (ja) 2025-11-18
JP7379446B2 (ja) 2023-11-14
EP3345928A1 (en) 2018-07-11
CN108026174A (zh) 2018-05-11
KR20180030856A (ko) 2018-03-26
EA201890028A1 (ru) 2018-08-31
SI3115376T1 (sl) 2018-12-31
US20240109966A1 (en) 2024-04-04
CN108026174B (zh) 2023-02-17
ES2812303T3 (es) 2021-03-16
MX2018000344A (es) 2018-03-14
US20160368988A1 (en) 2016-12-22
KR102709815B1 (ko) 2024-09-24
EP3757129A1 (en) 2020-12-30
US20190211100A1 (en) 2019-07-11
AU2016293942B2 (en) 2022-06-16
DK3115376T3 (en) 2018-11-26
TR201816055T4 (tr) 2018-11-21
NZ739165A (en) 2020-11-27
ES2693596T3 (es) 2018-12-12
JP2023181462A (ja) 2023-12-21
LT3115376T (lt) 2018-11-12
EP3345928B1 (en) 2020-06-24
WO2017010874A1 (en) 2017-01-19
HRP20181802T1 (hr) 2018-12-28
HUE042039T2 (hu) 2019-06-28
IL321912A (en) 2025-09-01
EP3115376A1 (en) 2017-01-11
US9914777B2 (en) 2018-03-13
SMT201800562T1 (it) 2018-11-09
EP3115376B1 (en) 2018-09-05
PT3115376T (pt) 2018-11-15
JP2018520169A (ja) 2018-07-26

Similar Documents

Publication Publication Date Title
MX2022008124A (es) Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano.
PH12019502730A1 (en) Method of manufacturing bispecific antibodies and therapeutic use of such antibodies
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
MX2024006992A (es) Anticuerpos contra ligando 1 de muerte programada.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX2015010427A (es) Anticuerpos anti-tnf-alfa altamente galactosilados y sus usos.
MX356288B (es) Anticuerpos biespecificos igg4 modificados de secuencia simetrica.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX370651B (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización.
EP4477668A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2019008123A3 (en) CELLS, VERTEBRATES, POPULATIONS AND METHODS
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
NZ629296A (en) Humanized antibodies that recognize alpha-synuclein
NZ708033A (en) Anti-blood dendritic cell antigen 2 antibodies and uses thereof
SG10201808837RA (en) Anti-egfr antibodies and antibody drug conjugates
NZ738979A (en) Pd-1 antibodies
EA035160B9 (ru) Антитела к st2 и их применение
SG10201914126RA (en) Anti-ox40 antibodies and their uses
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MX2015010428A (es) Anticuerpos anti-her2 altamente galactosilados y sus usos.
PH12014501439A1 (en) Plant artificial seeds having multilayers and methods for the production thereof
WO2015138600A3 (en) Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
MY177062A (en) Cd37-binding molecules and immunoconjugates thereof
SG178886A1 (en) Humanized anti-cdcp1 antibodies
EP4371570A3 (en) Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b